Inhibiting histone deacetylases suppresses glucose metabolism and hepatocellular carcinoma growth by restoring FBP1 expression

Decreased Expression of Fructose-1,6-bisphosphatase Associates with Glucose Metabolism and Tumor Progression in Hepatocellular Carcinoma

(2016) H. Hirata et al.   CANCER RESEARCH

Down Expression of FBP1 Is a Negative Prognostic Factor for Non–Small-Cell Lung Cancer

(2015) Huaying Sheng et al.   CANCER INVESTIGATION

Expression of the class 1 histone deacetylases HDAC8 and 3 are associated with improved survival of patients with metastatic melanoma

(2015) James S Wilmott et al.   MODERN PATHOLOGY

Down-regulation of FBP1 by ZEB1-mediated repression confers to growth and invasion in lung cancer cells

(2015) Juan Zhang et al.   MOLECULAR AND CELLULAR BIOCHEMISTRY

Class I HDACs Are Mediators of Smoke Carcinogen-Induced Stabilization of DNMT1 and Serve as Promising Targets for Chemoprevention of Lung Cancer

(2014) S. A. Brodie et al.   Cancer Prevention Research

Expression of Histone Deacetylases HDAC1, HDAC2, HDAC3, and HDAC6 in Invasive Ductal Carcinomas of the Breast

(2014) Jinwon Seo et al.   Journal of Breast Cancer

New and emerging HDAC inhibitors for cancer treatment

(2014) Alison C. West et al.   JOURNAL OF CLINICAL INVESTIGATION

Fructose-1,6-bisphosphatase opposes renal carcinoma progression

(2014) Bo Li et al.   NATURE

Differential expression of histone deacetylases HDAC1, 2 and 3 in human breast cancer - overexpression of HDAC2 and HDAC3 is associated with clinicopathological indicators of disease progression

(2013) Berit Maria Müller et al.   BMC CANCER

Loss of FBP1 by Snail-Mediated Repression Provides Metabolic Advantages in Basal-like Breast Cancer

(2013) Chenfang Dong et al.   CANCER CELL

BRCA1 is a negative modulator of the PRC2 complex

(2013) Lan Wang et al.   EMBO JOURNAL

HDAC Up-Regulation in Early Colon Field Carcinogenesis Is Involved in Cell Tumorigenicity through Regulation of Chromatin Structure

(2013) Yolanda Stypula-Cyrus et al.   PLoS One

Cancer Genetics and Epigenetics: Two Sides of the Same Coin?

(2012) Jueng Soo You et al.   CANCER CELL

Reprogramming transcription by distinct classes of enhancers functionally defined by eRNA

(2011) Dong Wang et al.   NATURE

Promoter Hypermethylation Mediated Downregulation of FBP1 in Human Hepatocellular Carcinoma and Colon Cancer

(2011) Mingquan Chen et al.   PLoS One

Clinical significance of histone deacetylases 1, 2, 3, and 7: HDAC2 is an independent predictor of survival in HCC

(2011) Karl Quint et al.   VIRCHOWS ARCHIV

Histone Deacetylase (HDAC) 1 and 2 Expression and Chemotherapy in Gastric Cancer

(2010) Kathrin Mutze et al.   ANNALS OF SURGICAL ONCOLOGY

High Efficacy of Panobinostat Towards Human Gastrointestinal Stromal Tumors in a Xenograft Mouse Model

(2009) G. Floris et al.   CLINICAL CANCER RESEARCH

The HDAC inhibitor panobinostat (LBH589) inhibits mesothelioma and lung cancer cells in vitro and in vivo with particular efficacy for small cell lung cancer

(2009) M. C. Crisanti et al.   MOLECULAR CANCER THERAPEUTICS

Warburg effect revisited: an epigenetic link between glycolysis and gastric carcinogenesis

(2009) X Liu et al.   ONCOGENE

Reprogramming epigenetic silencing: artificial transcription factors synergize with chromatin remodeling drugs to reactivate the tumor suppressor mammary serine protease inhibitor

(2008) A. S. Beltran et al.   MOLECULAR CANCER THERAPEUTICS

Is Akt the “Warburg kinase”?—Akt-energy metabolism interactions and oncogenesis

(2008) R. Brooks Robey et al.   SEMINARS IN CANCER BIOLOGY